# EDGAR Filing Document

**Accession Number:** 0001909817
**File Stem:** 0001909817-26-000005
**Filing Date:** 2026-2
**Character Count:** 9179
**Document Hash:** 91c3c2729ea2101811e017e8481e9633
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001909817-26-000005.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001909817-26-000005

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260212

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Boyer David W.
- **CENTRAL INDEX KEY:** 0001909817

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-22705
- **FILM NUMBER:** 26643973

**MAIL ADDRESS:**
- **STREET 1:** C/O NEUROCRINE BIOSCIENCES, INC.
- **STREET 2:** 12780 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEUROCRINE BIOSCIENCES INC
- **CENTRAL INDEX KEY:** 0000914475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 330525145
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6027 EDGEWOOD BEND COURT
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 617-7600

**MAIL ADDRESS:**
- **STREET 1:** 6027 EDGEWOOD BEND COURT
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Boyer David W.<br><sub>(Last) (First) (Middle)</sub><br>6027 EDGEWOOD BEND CT.<br><sub>(Street)</sub><br>SAN DIEGO, CA 92130<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Corp. Affairs Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NEUROCRINE BIOSCIENCES INC [ NBIX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-12 |  | M |  | 1600 | A | $0 | 6313 | D |  |
| Common Stock | 2026-02-12 |  | F |  | 864<sup>(1)</sup> | D | $123.10 | 5449 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 1541 | A | $0 | 6990 | D |  |
| Common Stock | 2026-02-13 |  | F |  | 832<sup>(1)</sup> | D | $124.12 | 6158 | D |  |
| Common Stock | 2026-02-13 |  | M |  | 1811 | A | $0 | 7969 | D |  |
| Common Stock | 2026-02-13 |  | F |  | 978<sup>(1)</sup> | D | $124.12 | 6991 | D |  |
| Common Stock | 2026-02-13 |  | A |  | 9968<sup>(2)</sup> | A | $0 | 16959 | D |  |
| Common Stock | 2026-02-13 |  | F |  | 5378<sup>(1)</sup> | D | $124.12 | 11581 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(3)</sup> | 2026-02-12 |  | M |  |  | 1600 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1600 | $0 | 4801 | D |  |
| Restricted Stock Unit | <sup>(3)</sup> | 2026-02-13 |  | M |  |  | 1541 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 1541 | $0 | 3083 | D |  |
| Restricted Stock Unit | <sup>(3)</sup> | 2026-02-13 |  | M |  |  | 1811 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 1811 | $0 | 1812 | D |  |
| Stock Option | $124.12 | 2026-02-13 |  | A |  | 31234 |  | <sup>(7)</sup> | 2036-02-13 | Common Stock | 31234 | $0 | 31234 | D |  |
| Restricted Stock Unit | <sup>(3)</sup> | 2026-02-13 |  | A |  | 5479 |  | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 5479 | $0 | 5479 | D |  |

---

### Footnotes:

(1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

(2) On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.

(3) Each RSU represents a contingent right to receive one share of the Issuer's common stock .

(4) This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.

(5) This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, vested as to 1,541 shares on February 13, 2026, and will vest as to 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award.

(6) This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, vested as to 1,811 shares on February 13, 2026, and will vest as to 1,812 shares on February 13, 2027, subject to the terms and conditions of the award.

(7) Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

(8) The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

**Signature:** /s/ Darin Lippoldt, Attorney-in-Fact  
**Date:** 2026-02-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**